GRAIL, Inc. (GRAL)
NASDAQ: GRAL · Real-Time Price · USD
86.36
+1.36 (1.60%)
At close: Oct 28, 2025, 4:00 PM EDT
86.36
0.00 (0.00%)
Pre-market: Oct 29, 2025, 9:02 AM EDT
GRAIL Revenue
GRAIL had revenue of $35.54M in the quarter ending June 30, 2025, with 11.18% growth. This brings the company's revenue in the last twelve months to $134.29M, up 22.37% year-over-year. In the year 2024, GRAIL had annual revenue of $125.60M with 34.90% growth.
Revenue (ttm)
$134.29M
Revenue Growth
+22.37%
P/S Ratio
21.80
Revenue / Employee
$134,285
Employees
1,000
Market Cap
3.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 125.60M | 32.49M | 34.90% |
| Dec 31, 2023 | 93.11M | 37.56M | 67.61% |
| Jan 1, 2023 | 55.55M | 40.94M | 280.17% |
| Jan 2, 2022 | 14.61M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
GRAL News
- 2 days ago - GRAIL: Buy Τhe Test That Could Redefine Cancer Screening - Seeking Alpha
- 8 days ago - GRAIL, Inc. (GRAL) Discusses PATHFINDER 2 Study Results and Clinical Program in Multi-Cancer Early Detection Transcript - Seeking Alpha
- 9 days ago - GRAIL, Inc. Announces $325.0 Million Private Placement Financing - PRNewsWire
- 9 days ago - GRAIL and University of Oxford to Present Long-Term Data From the SYMPLIFY Study Evaluating the Galleri® Multi-Cancer Early Detection Test in Symptomatic Individuals at the Early Detection of Cancer Conference (EDCC) - PRNewsWire
- 11 days ago - GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings - PRNewsWire
- 11 days ago - What's Happening With GRAIL Stock? - Forbes
- 13 days ago - Samsung and GRAIL Announce Strategic Collaboration to Bring GRAIL's Galleri® Multi-Cancer Early Detection Test to Asia - PRNewsWire
- 4 weeks ago - Grail: A Speculative Buy - Seeking Alpha